Sulfinpyrazone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sulfinpyrazone
Sulfinpyrazone.svg
Systematic (IUPAC) name
1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
Clinical data
Trade names Apo-sulfinpyrazone
AHFS/Drugs.com monograph
MedlinePlus a682339
Legal status
?
Routes oral intravenous
Pharmacokinetic data
Protein binding 98–99%
Metabolism hepatic
Excretion renal
Identifiers
CAS number 57-96-5 YesY
ATC code M04AB02
PubChem CID 5342
DrugBank DB01138
ChemSpider 5149 YesY
UNII V6OFU47K3W YesY
KEGG D00449 YesY
ChEBI CHEBI:9342 YesY
ChEMBL CHEMBL832 YesY
Chemical data
Formula C23H20N2O3S 
Mol. mass 404.48 g/mol
 YesY (what is this?)  (verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications[edit]

Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).[1]

Synthesis[edit]

Sulfinpyrazone synthesis 01.svg

References[edit]

  1. ^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.